Ixovex-1, a novel oncolytic E1B-mutated adenovirus

Area of Science:

• Oncolytic virotherapy
• Adenovirus engineering
• Cancer biology

Background:

• Oncolytic viruses offer a promising cancer treatment strategy.
• Current oncolytic adenoviruses require further optimization for cancer selectivity and efficacy.
• Modulating viral gene expression is a key approach to enhance oncolytic virus properties.

Purpose of the Study:

• To characterize a novel oncolytic adenovirus, Ixovex-1, engineered for enhanced cancer selectivity.
• To evaluate the in vitro and in vivo performance of Ixovex-1.
• To assess the impact of E1B-156R isoform overexpression on oncolytic activity.

Main Methods:

• Construction of a recombinant adenovirus (Ixovex-1) with a mutation in the E1B-93R splice acceptor site.
• In vitro assessment of Ixovex-1 replication in normal and cancer cell lines.
• In vivo anti-tumor efficacy studies in a mouse lung carcinoma model.
• Complementation experiments to validate the role of E1B-156R.

Main Results:

• Ixovex-1 exhibited cancer-selective replication in vitro.
• Ixovex-1 significantly inhibited tumor growth and prolonged survival in vivo.
• Overexpression of E1B-156R enhanced the oncolytic index of other adenovirus types.
• Ixovex-1 demonstrated superior competency compared to deleted-region viruses, retaining a functional E3B region.

Conclusions:

• Ixovex-1 represents a novel oncolytic adenovirus with improved cancer selectivity and efficacy.
• The E1B-156R splice isoform plays a crucial role in enhancing oncolytic adenovirus activity.
• Ixovex-1's design, including a functional E3B region, contributes to its superior in vivo performance.